—

Smith & Nephew SNATS Inc (SNN) — the peer cohort

As of 2026-10-15 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Smith & Nephew SNATS Inc ranks 7 of 10 in its cohort on the Closelooknet composite (57/100) — the cohort is led by Halozyme Therapeutics Inc at 75/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
SNN Smith & Nephew SNATS Inc 57 30 55 73 info 21.3%
DXCM DexCom Inc 66 87 80 34 watch 9.8%
GMED Globus Medical 60 37 64 57 bear 24.7%
SECT-B.ST Sectra AB (publ) 60 83 66 11 watch 6.4%
CEVI.ST CellaVision AB 55 71 69 29 bull 12.6%
SYK Stryker Corporation 52 27 66 43 bear 27.9%
SHL.DE Siemens Healthineers AG 49 62 47 55 bull 17.5%
HALO Halozyme Therapeutics Inc 75 98 94 47 ok 0.7%
ONC BeiGene, Ltd. 64 84 63 30 ok 2.9%
MEDP Medpace Holdings Inc 64 87 74 28 ok 7.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-15

Quick answers

Who are Smith & Nephew SNATS Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: DexCom Inc (DXCM), Globus Medical (GMED), Sectra AB (publ) (SECT-B.ST), CellaVision AB (CEVI.ST), Stryker Corporation (SYK), Siemens Healthineers AG (SHL.DE), Halozyme Therapeutics Inc (HALO), BeiGene, Ltd. (ONC) and others.

How does SNN score against its peers?

Smith & Nephew SNATS Inc's composite reads 57/100, ranking 7 of 10 in its cohort as of 2026-10-15; the cohort's highest composite is Halozyme Therapeutics Inc at 75/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.